Organon & Co.
 | |
| Industry | pharmaceutical company |
|---|---|
| Founded | November 2007 |
| Headquarters | , |
| Revenue | 6,174,000,000 United States dollar (2022)  |
| 1,122,000,000 United States dollar (2022) | |
| 917,000,000 United States dollar (2022) | |
Organon was a pharmaceutical company headquartered in Oss, Netherlands. In November 2007, Schering-Plough Corporation, based in New Jersey, USA, acquired Organon, active pharmaceutical ingredient producer Diosynth (separate from Organon until 2004),[1] and its veterinary pharmaceutical sister company Intervet from Akzo Nobel.[2] In November 2009, Schering-Plough merged with Merck & Co. under the name Merck & Co., known as Merck Sharp & Dohme or MSD outside the United States and Canada.[3] Organon deals in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, HRT and anesthesia. Organon sells to international markets.
History
Organon was founded by Dr. Saal van Zwanenberg in Oss, the Netherlands, in 1923 as Zwanenberg-Organon. Its first product was insulin in 1923.[4] In the thirties it manufactured estrogens.[4] In 1948, Organon acquired the Newhouse research site in Scotland, United Kingdom. The production of cortisone was initiated in 1953.[1] In 1962 it bought the stock of the Nederlandsche Cocaïnefabriek. The now named Koninklijke Zwanenberg-Organon (KZO) fused with the fibre producer AKU in 1969 to become AKZO, later Akzo Nobel. Organon was the human health care business unit of Akzo Nobel and transferred its headquarters to New Jersey, USA[5] while the main headquarters of Akzo Nobel remained in Arnhem, and has since moved to Amsterdam. Manufacturing facilities are in the Netherlands, Germany, the United Kingdom, Ireland, China, Japan, and the USA.
Products
Products include: Bridion, Esmirtazapine, Remeron, Remeron SolTab, Sustanon, Deca-Durabolin, Pregnyl, Implanon, NuvaRing, Marvelon, Desolett and a variety of other contraceptive products.
Research compounds
During its period of independent operation, Organon developed a large number of compounds which were never adopted for medical use, but continue to be used for a variety of scientific research. Notable compounds include:
- Org 12,962
- Org 20599
- Org 21465
- Org 25435
- Org 25935
- Org 26576
- Org 27569
- Org 28312
- Org 28611
- Org 37,684
Kickback scandal
On Oct. 16, 2014, the government of the United States charged Organon with misrepresentation of drug prices and providing improper financial incentives (kickbacks) to nursing homes for market-shares discounts to encourage the use of Remeron. Organon paid $622,350 in restitution under the Federal Anti-Kickback Statute.[citation needed]
References
- ^ a b "81 Years of Organon at a Glance". Organon. Archived from the original on 9 March 2005. Retrieved 19 June 2010.
- ^ "Schering-Plough Acquires Organon BioSciences". Medical Net News. 20 November 2007. Retrieved 19 June 2010.
- ^ "Merck and Schering-Plough to Complete Merger Today" (Press release). Merck & Co. November 3, 2009. Archived from the original on November 7, 2009. Retrieved 2010-07-16.
{{cite press release}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - ^ a b "Organon History 1920's". Organon. Archived from the original on 9 December 2006. Retrieved 19 June 2010.
- ^ "Why the Germany and Much of the European Union is Losing its Pharmaceutical Industry" (PDF). American Enterprise Institute. Retrieved 21 February 2013.
External links
- Organon official website (redirects to merck.com)
- Schering-Plough (redirects to merck.com)
- Intervet International (redirects to merck-animal-health.com)
- Photo of Organon Insulin carton, 1930
- Report to the Insulin Committee on Insulins in Europe, 1925 (University of Toronto)-page 26-Organon
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |